BiotechTube

Lacosamide

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Epilepsy With and Without Secondary Generalization

Conditions

Focal Epilepsy With and Without Secondary Generalization

Trial Timeline

Jul 1, 2012 → Jul 1, 2015

NCT ID
NCT01673282

About Lacosamide

Lacosamide is a pre-clinical stage product being developed by UCB for Focal Epilepsy With and Without Secondary Generalization. The current trial status is completed. This product is registered under clinical trial identifier NCT01673282. Target conditions include Focal Epilepsy With and Without Secondary Generalization.

What happened to similar drugs?

4 of 10 similar drugs in Focal Epilepsy With and Without Secondary Generalization were approved

Approved (4) Terminated (1) Active (6)
✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
✅DapagliflozinAstraZenecaApproved
✅Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
✅Levetiracetam + Carbamazepine + LamotrigineUCBApproved
🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
🔄Gadoxetic Acid Disodium (Primovist, BAY86-4873)BayerPhase 3
🔄XEN1101 + PlaceboXenon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT03559673Pre-clinicalCompleted
NCT04627285Phase 3Completed
NCT02710890Phase 2/3Completed
NCT02582866Phase 3Completed
NCT02477839Phase 3Completed
NCT02124564Phase 3Completed
NCT01969851Phase 2Completed
NCT01921205Phase 3Completed
NCT01724918Phase 2Terminated
NCT01832038Phase 3Completed
NCT01673282Pre-clinicalCompleted
NCT01530386Phase 1Completed
NCT01484977Phase 3Completed
NCT01236001Pre-clinicalCompleted
NCT01118962Phase 2Completed
NCT01235403ApprovedCompleted
NCT01118949Phase 2Completed
NCT00938431Phase 2Completed
NCT00955357ApprovedCompleted
NCT00771927Pre-clinicalCompleted

Competing Products

20 competing products in Focal Epilepsy With and Without Secondary Generalization

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
35
DapagliflozinAstraZenecaApproved
43
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
35
CCX140-BAmgenPhase 2
27
PF-06730512PfizerPhase 2
27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
43
VX-147Vertex PharmaceuticalsPhase 2
35
VX-147Vertex PharmaceuticalsPhase 1
29
IXPVertex PharmaceuticalsPhase 1
29
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
35
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
29
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
42
VivaglobinCSLPhase 2
35
UCB0942UCBPhase 2
27
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
43
Brivaracetam + BrivaracetamUCBPhase 2
35
LacosamideUCBPhase 2
27
UCB0942 + UCB0942 + PlaceboUCBPhase 2
35
ARGX-117ArgenxPhase 2
36
Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
44